Goodman Advisory Group LLC Sells 283 Shares of AstraZeneca PLC (NASDAQ:AZN)

Goodman Advisory Group LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,201 shares of the company’s stock after selling 283 shares during the period. Goodman Advisory Group LLC’s holdings in AstraZeneca were worth $1,496,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC raised its position in shares of AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares in the last quarter. Creative Planning lifted its holdings in shares of AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the period. Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $269,000. Finally, Soros Fund Management LLC increased its stake in AstraZeneca by 8.2% in the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after acquiring an additional 201,233 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Up 0.6 %

AstraZeneca stock opened at $68.58 on Tuesday. The firm has a 50 day moving average price of $71.27 and a two-hundred day moving average price of $77.08. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The firm has a market cap of $212.64 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 1.22 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business earned $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. Equities analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.